Cite
HARVARD Citation
Blazejak, C. et al. (n.d.). Response to brentuximab vedotin in advanced stage MF/Sézary syndrome with low CD-30 expression: "real-life" data of the German Cutaneous Lymphoma Network. European journal of cancer. pp. S16-S17. [Online].